Investigational drug · Phase 2
Adebelimab
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Advanced Solid Tumors, Recurrent or Metastatic Cervical Cancer.
Phase 2Last checked: Nov 19, 2026Latest source record: Jun 6, 2025 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
2
2 still active
All registered trials
13
Any phase or sponsor naming "Adebelimab"
First trial start
2025
Mar 28, 2025
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Adebelimab", any sponsor or status.
- Phase 212
Conditions studied
As listed on its trial records.
- Advanced Solid Tumors
- Recurrent or Metastatic Cervical Cancer
Approved drugs for the same conditions: Cervical cancer · Oncology
Largest trials
Live from ClinicalTrials.gov: studies naming "Adebelimab" as an intervention, largest first.
Shanghai Hengrui Pharmaceutical Co., Ltd.Industry
NCT06895928 · 400 participants (planned) · Start Mar 28, 2025 · Primary completion Dec 2028
Drug: SHR-A2102; Bevacizumab Injection and 3 more · For: Advanced Solid Tumors
Sites: Taiyuan, China
Xian-Jun YuAcademic, hospital or other
NCT07348042 · 198 participants (planned) · Start Sep 7, 2025 · Primary completion Mar 31, 2027
Drug: RGL-270 Injection; Adebelimab Injection · For: Tumor, Solid
Sites: Shanghai, China
- Adebrelimab Plus Carboplatin/Paclitaxel Followed by Adebelizumab with or Without Apatinib in the Treatment of Advanced Recurrent/Metastatic Endometrial Cancer (A-CAPE): a Multicenter, Randomized, Controlled, Open-Label Clinical TrialPivotal-lookingNot yet recruiting
Peking Union Medical College HospitalAcademic, hospital or other
NCT06771154 · 140 participants (planned) · Start Apr 1, 2025 · Primary completion Apr 1, 2029
Drug: Adebelimab Combined with Apatinib; Adebelimab · For: Recurrent/Metastatic Endometrial Cancer
Sites: Beijing, China, China
- Study of Paclitaxel Polymeric Micelles Combined With HP and Adebelimab Versus Taxane Combined With HP as First-Line Treatment for Advanced HER2-Positive Breast CancerPivotal-lookingRecruiting
Fudan UniversityAcademic, hospital or other
NCT07581795 · 140 participants (planned) · Start Jul 28, 2026 · Primary completion Feb 28, 2029
Drug: Paclitaxel polymer micelles combined with trastuzumab, pertuzumab, and adrelumab; Taxanes combined with trastuzumab and pertuzumab. · For: Advanced HER2-positive Breast Cancer
Sites: Shanghai, China
Shanghai Hengrui Pharmaceutical Co., Ltd.Industry
NCT06589778 · 124 participants (planned) · Start Sep 27, 2024 · Primary completion Apr 30, 2026
Drug: SHR-A2102; Adebelimab (SHR-1316) and 1 more · For: Non-Small Cell Lung Cancer
Sites: Shanghai, China
- SHR-A1811 Combination Regimen for the Treatment of Recurrent or Metastatic Cervical CancerPivotal-lookingRecruiting
Suzhou Suncadia Biopharmaceuticals Co., Ltd.Industry
NCT06859775 · 100 participants (planned) · Start Apr 25, 2025 · Primary completion Oct 2026
Drug: SHR-A1811; Adebelimab injection and 4 more · For: Recurrent or Metastatic Cervical Cancer
Sites: Beijing, China
Peking Union Medical College HospitalAcademic, hospital or other
NCT07670273 · 70 participants (planned) · Start Apr 29, 2026 · Primary completion Apr 29, 2027
Drug: Trastuzumab Rezetecan; Adebrelimab and 1 more · For: Biliary Tract Neoplasms Immunotherapy
Sites: Beijing, China
Peking Union Medical College HospitalAcademic, hospital or other
NCT07704177 · 70 participants (planned) · Start Apr 15, 2026 · Primary completion Apr 15, 2027
Drug: Trastuzumab Rezetecan; Adebrelimab and 1 more · For: Biliary Tract Neoplasms Immunotherapy
Sites: Beijing, China
Fudan UniversityAcademic, hospital or other
NCT07638852 · 58 participants (planned) · Start Feb 2, 2026 · Primary completion Jun 30, 2028
Drug: Adebelimab; Bevacizumab and 1 more · For: TNBC, Triple Negative Breast Cancer; Brain Metastasases
Sites: Shanghai, China
- A Study of Adebelimab Combined With Chemotherapy as a First-line Treatment Sequential Treatment for Extensive-stage Small Cell Lung CancerNot yet recruiting
Fujian Cancer HospitalGovernment (non-federal)
NCT06614621 · 43 participants (planned) · Start Feb 1, 2025 · Primary completion Dec 1, 2027
Drug: Adebrelimab +Etoposide+Platinum-based drugs; Maintenance treatment period: · For: Extensive-Stage Small Cell Lung Cancer
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Advanced Solid Tumors
- SKB264MK-2870, Sacituzumab TirumotecanPhase 353 trials
Merck & Co. · Non-Small Cell Lung Cancer, Non-small Cell Lung Cancer, Cervical Cancer
- IvonescimabAK112, SMT112Phase 349 trials
Akeso · Non-Small Cell Lung Cancer, Advanced Malignant Tumors, Advanced Solid Tumors
- AdebrelimabSHR-8068, HRS -4642Phase 341 trials
Suzhou Suncadia Biopharmaceuticals Co., Ltd. · Non-small Cell Lung Cancer, Advanced or Metastatic Non-small Cell Lung Cancer, Advanced Solid Tumors
- AdabelimumabSHR-A2102, SHR2554Phase 320 trials
Suzhou Suncadia Biopharmaceuticals Co., Ltd. · Advanced Solid Tumors, Prostate Cancer, Advanced Urothelial Carcinoma
- SG001enlonstobart, Enlonstobart will be administrated on a 14-day cyclePhase 315 trials
CSPC Megalith Biopharmaceutical Co.,Ltd. · HER2-positive Gastric Cancer, Esophageal Squamous Cell Carcinoma, Head and Neck Squamous Cell Carcinoma
- SYS6010Phase 315 trials
CSPC Megalith Biopharmaceutical Co.,Ltd. · Non-Small Cell Lung Cancer, Esophageal Squamous Cell Carcinoma, Head and Neck Squamous Cell Carcinoma
- YL201Tambotatug Pelitecan, Tam-PeliPhase 311 trials
MediLink Therapeutics (Suzhou) Co., Ltd. · Advanced Solid Tumor, Small Cell Lung Cancer, Metastatic Pancreatic Cancer
- PD-1 inhibitorPhase 38 trials
BioAtla, Inc. · Advanced Solid Tumors, Gastric or Gastroesophageal Junction Adenocarcinoma, NSCLC (Advanced Non-small Cell Lung Cancer)
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.